CLOVER HEALTH INVESTMENTS COCLOV
ASignal's systematic analysis rates CLOV as Neutral.
Reflects the latest available analysis · analyzed Sep 11, 2026
The case on CLOV
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong year-over-year revenue growth (55.6%)
- Positive free cash flow of $69.05M
- No debt on balance sheet
- High growth score (0.9) indicating strong expansion metrics
- Operating cash flow of $77.03M supports business operations
- RSI at 81.12 indicates overbought conditions
- Negative MACD despite histogram contraction
- Price trading above upper Bollinger Band (4.59), suggesting premium valuation
- Negative net margin (-0.74%) and return on equity (-5.10%)
- EV/EBITDA of -125.79x reflects unprofitability
- Low Reddit engagement (2 mentions)
See the full verdict on CLOV
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CLOV
Most investors never get a second opinion, let alone several. ASignal runs CLOV past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.